



GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission:
Transforming the standard of care in gynecologic oncology

NEW TREATMENT OPTION ON THE HORIZON FOR PLATINUM-RESISTANT OVARIAN CANCER


Positive Results from GOG-3073 (ROSELLA), Corcept's Phase 3 Trial

Corcept Therapeutics announced significant progress in the fight against platinum-resistant ovarian cancer (PROC) with the successful outcome of its pivotal Phase 3 Trial CORT125134-556/GOG-

3073/ROSELLA*, a Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer. The trial, which investigated the combination of relacorilant and nab-paclitaxel, met its primary endpoint, showing a 30% reduction in the risk of disease progression in patients compared to nab-paclitaxel alone. This breakthrough also resulted in a notable improvement in overall survival, with patients on the combination therapy experiencing a median overall survival of 16 months, compared to 11.5 months for those receiving nab-paclitaxel alone. These promising results bring Corcept closer to submitting a New Drug Application (NDA) in the U.S. and a Marketing Authorization Application (MAA) in Europe.



Alexander B. Olawaiye, MD



Domenica Lorusso, MD, PhD

Dr. Alexander Olawaiye, Director of Gynecological Cancer Research at Magee-Women's Hospital of the University of Pittsburgh, and Dr. Domenica Lorusso, Director of the Gynecological Oncology Unit at Humanitas Hospital San Pio X in Milan, both served as Principal Investigators for the ROSELLA trial. Both researchers emphasized the significant treatment challenges posed by platinum-resistant ovarian cancer and the potential of this combination therapy to reshape patient outcomes. "Relacorilant plus nab-paclitaxel represents an important advancement in treatment for these patients, offering new hope for better survival without increasing the safety burden," said Dr. Olawaiye.

The success of the ROSELLA trial paves the way for relacorilant to potentially become a new standard of care for platinum-resistant ovarian cancer, offering improved survival with no additional safety concerns. As Corcept plans to present full trial results at an upcoming medical conference and submit regulatory applications, the company, in collaboration with The GOG Foundation, Inc. and other global oncology networks, including the European Network of Gynaecological Oncological Trial groups (ENGOT), the Asia-Pacific Gynecologic Oncology Trials Group (APGOT), the Latin American Cooperative Oncology

Group (LACOG) and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) continues its commitment to advancing treatments for this challenging disease.

"This is just another example of the GOG-F fulfilling our mission to Transform the Standard of Care in Women's Cancer", notes GOG-F President Dr. Thomas Herzog, and Gynecologic Oncologist at the University of Cincinnati, "we extend our sincere appreciation to all the organizations and patients involved in the trial and expresses gratitude for the leadership and staff at Corcept for their unwavering partnership and support in making this trial a success".

[Click here](#) to read the full press release.

THE NATIONAL GYNECOLOGIC ONCOLOGY 2025 ANNUAL FELLOWS FORUM



The GOG Foundation, Inc. is proud to announce the National Gynecologic Oncology Fellows Forum, a dynamic program aimed at cultivating the next generation of leaders in gynecologic oncology.



As Dr. Thomas Herzog, President of the GOG Foundation, emphasizes, "Investing in the development of fellows and young investigators is essential to the future of gynecologic oncology research and clinical practice. By equipping emerging researchers with leadership skills, effective communication strategies, and mentorship, we ensure that they are prepared to drive forward innovation and make lasting contributions to the field."

The National Gynecologic Oncology Fellows Forum will provide participants with a unique opportunity to engage in focused sessions, interactive workshops, and mentorship from experienced faculty members, refining their expertise and advancing their careers. The 2025 Program taking place April 2-5, 2025 at the Fontainebleau Hotel in Miami Beach, Florida accepted 42 Fellows to present research during the three-day program.

Dr. Mario Leitao, the program chair, expresses his excitement about partnering with the GOG Foundation, stating, "It is an incredible opportunity to collaborate with the GOG Foundation in offering this forum. Mentoring the next generation of gynecologic oncologists is not just a responsibility, but an incredible opportunity to shape the future of the field and a vital part of our mission. The Fellows Forum is an invaluable platform for young investigators to gain the knowledge, support, and networking opportunities they need to excel in their careers and contribute meaningfully to the field."



Along with Dr. Leitao, the esteemed program directors include Dr. William Burke, Dr. Ramez Eskander, Dr. Heidi Gray, Dr. Kenneth Kim, Dr. Thomas Krivak, Dr. Martin Martino, Dr. Susan Modesitt, Dr. Brian Slomovitz, Dr. J. Michael Straughn, Dr. Todd Tillmanns, and Dr. Christine Walsh. Together, they are committed to advancing the careers of young investigators and ensuring their continued success.

Looking ahead, the GOG Foundation is excited to announce the 2026 National Gynecologic Oncology Fellows Forum, which will take place April 29 – May 2, 2026, at the Fairmont Princess Resort Hotel in Scottsdale, Arizona. A Call for Abstracts for the 2026 program will open in Fall 2025.

The GOG Foundation remains committed to fostering the next generation of gynecologic oncologists and looks forward to continuing this valuable partnership.

THE ORIGIN OF THE CHAMELEON TRIAL

an SGO/GOG Foundation, Inc. Success Story

I joined SGO BRIDGES while finishing my fellowship at Memorial Sloan Kettering Cancer Center. In fellowship, I developed a strong clinical interest in low grade serous ovarian carcinoma under the guidance and mentorship of Dr. Rachel Grisham. As a part of SGO BRIDGES, I sought to leverage our prior research into the molecular drivers of low grade serous ovarian carcinoma to design a trial that provided a better, more targeted treatment in the upfront setting. Too often in oncology, we look to the recurrent setting with our cutting edge treatments. Instead, we wanted to push the envelope and get these exciting, molecularly-targeted therapies into the front line for our patients.



Beryl Manning-Geist, MD, FACOG

Assistant Professor,
Division of Gynecologic Oncology
Department of Gynecology and Obstetrics
Winship Cancer Institute,
Emory University School of Medicine

The CHAMELEON trial is for patients with low grade serous ovarian carcinoma who have residual disease after primary debulking surgery, or for patients who need neoadjuvant chemotherapy. It replaces our typical treatment of carboplatin and paclitaxel with hormonal blockade plus avutometinib and defactinib. This is the same combination (minus the hormonal blockade) that is under investigation in the Phase III RAMP 301 trial.

We opened this trial in partnership with Verastem Oncology in 2024 at Memorial Sloan Kettering Cancer Center, and we anticipate the trial will be open at Winship Cancer Institute at Emory University in Atlanta, Georgia in Spring 2025, where I have joined the faculty. We look forward to continuing enrollment on this trial and advancing care for patients with low grade serous ovarian cancer.

UPDATES FROM THE GYNECOLOGIC CANCER INTERGROUP (GCIG)



The GOG Foundation, Inc. (GOG-F) continues its long-standing collaboration with the Gynecologic Cancer InterGroup (GCIG), whose vision is to end gynecologic cancer through global, collaborative research. The fall of 2024 marked several important events!

Cervical Cancer Consensus Conference on Clinical Research (CCCC-CR)

The inaugural CCCC-CR was held October 14-15, 2024 in Dublin, Ireland, prior to the IGCS Annual Meeting. The conference, led by Drs. Ana Oaknin, Dearbhaille O'Donnell, and David Tan addressed topics of diagnosis and staging, early-stage cervical cancer, locally advanced cervical cancer, and metastatic and recurrent disease. Approximately 100 participants from 33 member groups attended. GOG-F provided diverse expertise from representatives Dr. Michael Bookman (senior leader, clinical trials), Dr. Jyoti Mayadev (radiation oncology), Dr. Dmitriy Zamarin (medical oncology and translational science), Dr. Leslie Randall (gynecologic oncology), Dr. Allan Covens (early-stage management and clinical trials), Dr. Austin Miller (statistics). The Consensus statement will incorporate a global perspective, considering geographic differences in disease burden and resource constraints, and the publication is forthcoming.

Endometrial Cancer Consensus Conference on Clinical Research (ECCC-CR)

The consensus statement from the inaugural ECCC-CR held in November 2023 in Seoul, Korea was published in the Lancet Oncology in September 2024.

[Click here](#) to read the full abstract.

GCIG Leadership Updates

GCIG PRESIDENT

Michael A. Bookman, MD, Kaiser Permanente-San Francisco



In October 2024, Dr. Michael Bookman became the first ever GOG-F member inducted as the GCIG President. In this role, Dr. Bookman will continue to pursue his passion for promoting the alignment of global research agendas to reduce duplicative efforts, improving both operational efficiency and external validity of study results.

His contributions to the GCIG are transformational and include the iteration of strategic goals to focus on improving outcomes, promoting excellence in research, building the next GCIG generation, collaborating with partners, improving diversity, equity, and inclusivity, and enhancing sustainability, in addition to transitioning the group toward a focus on pragmatic study designs that can be conducted in all parts of the world and in lower resource settings.

Dr. Bookman will lead in this capacity for two years and then serve two additional years as the Immediate Past President. Please join us in congratulating Dr. Bookman! We are grateful for his service and dedication to this important role.

OVARIAN CANCER COMMITTEE & THE PHASE 2 COMMITTEE CO-CHAIRS

Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma
Róisín O'Cearbhaill, MD, Memorial Sloan Kettering Cancer Center

In addition, the GOG-F welcomes and congratulates Dr. Kathleen Moore and Dr. Róisín O'Cearbhaill who were recently elected to serve as the Ovarian Cancer Committee Co-Chairs and the Phase 2 Committee Co-chairs, respectively. Both Dr. Moore and Dr. O'Cearbhaill have been closely involved in the GCIG in past years and the GOG-F is grateful for their continued leadership and service. We are looking forward to their contributions and innovations in their respective roles.



Kathleen Moore, MD



Róisín O'Cearbhaill, MD

SPECIAL RECOGNITION

Philanthropy Sets the Wheels in Motion for Dr. David Mutch's Research on Endometrial Cancer

Congratulations to Dr. David Mutch for your groundbreaking research on endometrial cancer, made possible by the generous support of donors to The Foundation for Barnes-Jewish Hospital. Those early investments continue to accelerate discoveries, improve treatments, and expanded research opportunities including the Route 66 Endometrial Cancer SPORE.

Dr. Mutch states that, "Generous philanthropy has been an essential building block for life-changing endometrial cancer research progress. SPOREs encourage interdisciplinary research to move laboratory studies to patient care more quickly."



David Mutch, MD

Washington University School of Medicine
Siteman Cancer Center

[Click here](#) to read the full article

Top 50 Recruiting Sites GOG Partners/NRG Combined

1	The Ohio State University Comprehensive Cancer Center
2	University of Oklahoma Health Sciences Center
3	Women & Infants Hospital
4	University of Virginia
5*	Memorial Sloan Kettering Cancer Center NYU Langone Medical Center - NYU Clinical Cancer Center - Womens Cancer Program
6	Women's Cancer Center of Nevada
7*	Froedtert and The Medical College of Wisconsin Georgia Regents/Augusta University
8*	Washington University School of Medicine University of Colorado Hospital - Anschutz Cancer Pavilion
9	University of Rochester
10*	Oklahoma Cancer Specialists and Research Institute, LLC Indiana University Melvin and Bren Simon Comprehensive Cancer Center
11	HonorHealth Research and Innovation Institute
12	Abington Memorial Hospital - Asplundh Cancer Pavilion/Thomas Jefferson
13	Virginia Commonwealth University
14	Cleveland Clinic Foundation
15	Center of Hope
16	Northwestern University
17	Yale University
18	New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center
19	Duke University Medical Center
20	The Blavatnik Family - Chelsea Medical Center at Mount Sinai
21*	University of Iowa Hospitals and Clinics Rutgers Cancer Institute of NJ
22*	MD Anderson Cancer Center University of California San Diego Moores Cancer Center
23	University of Washington Fred Hutchinson Cancer Center (FHCC)/Seattle Cancer Care Alliance
24	Levine Cancer Institute, Atrium Health (Carolinas Medical Center)
25*	Texas Oncology - Fort Worth - SCRI Weill Cornell Medicine - New York Presbyterian Hospital
26*	University of Rochester UCLA Johnson Comprehensive Cancer Center The University of Arizona Cancer Center
27*	Western Pennsylvania Hospital/West Penn Hospital - Allegheny Health Network University of Pennsylvania University of Chicago Medical Center Swedish Medical Center
28*	Maine Medical Center Baystate Medical Center
29*	University of Alabama at Birmingham University of Cincinnati University of Nebraska Medical Center
30*	Oncology Associates of Oregon - Willamette Valley Cancer Institute and Research Center – SCRI Avera Cancer Institute Cedars Sinai Medical Center
31*	University of Wisconsin Advent Health Orlando University of Arkansas for Medical Sciences Lewis Cancer & Research Pavilion at St. Joseph's/Candler
32*	University of Michigan Minnesota Oncology Hematology, PA - Maplewood

**Note that each site in the designated ranking spots shared the same combined accrual numbers for that specific ranking.*

The GOG Foundation, Inc. Donates to the California Wildfire Relief



The GOG Foundation, Inc. has donated funds typically used for the GOG Investigators and Site Staff Meeting attendance raffle to the American Red Cross.

We express our deepest empathy and concern for those affected by the Southern California wild fires.

If you or anyone you know would like to contribute to this cause, please [click here](#) to make

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 20 clinical trials

- **9 Ovary**
- **3 Cervix**
- **8 Endometrium**



To search active trials visit our website by clicking Clinical Trials button below.

[Clinical Trials](#)

IN THE NEWS

GOG-3076 (OnPrime) Press Release


Genelux Achieved Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer.

- The Company continues to enroll patients in the ongoing pivotal Phase 3 OnPrime/GOG-3076 registration trial in platinum resistant/refractory ovarian cancer, with the primary endpoint of progression-free survival (Clinicaltrials.gov identifier [NCT05281471](#)), as well as continues to have productive discussions with the U.S. Food and Drug Administration (FDA).
- In response to a question seeking the FDA's guidance on their expectations regarding a confirmatory trial using the ongoing OnPrime/GOG-3076 trial, the FDA responded that "As stated previously, an interim analysis of overall survival (OS) should be planned at the time of the primary PFS analysis. If a clinically meaningful PFS advantage is demonstrated in the absence of a decrement in OS, this could potentially support traditional approval." The FDA further recommended Genelux request a pre-BLA meeting with FDA with topline safety and efficacy data following completion of the study to discuss next steps.

Why Phase 3 OnPrime/GOG-3076 Trial for your patients

- ✓ **No cap** on the number of prior lines
- ✓ **Platinum-refractory** patients eligible
- ✓ **Platinum optional** within Active Comparator Arm
- ✓ **No requirements** for tumor cell surface receptors/ligands or mutational status
- ✓ **No limitation** on the time from last platinum exposure

Phase 2 VIRO-15 results published in JAMA Oncology



[Click here](#) to read the full press release.

GOG-3111 (FTH-PIK-201) Press Release

FAETH THERAPEUTICS AND THE GOG FOUNDATION, INC. (GOG-F) LAUNCH FIRST PHASE 2 COMBINATION TRIAL FOR SAPANISERTIB-SERABELISIB IN PATIENTS WITH ENDOMETRIAL CANCER

AUSTIN, TX and PHILADELPHIA, PA—March 12, 2025—[Faeth Therapeutics](#) (Faeth), a clinical-stage biotechnology company focused on metabolism, and The GOG Foundation, Inc. (GOG-F), a not-for-profit organization with the purpose of promoting excellence in the quality and integrity of clinical and translational scientific research in the field of gynecologic malignancies, today announced the first patient has been dosed in its Phase 2 combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kα-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer.

The PI3K/AKT/mTOR pathway is the most frequently mutated pathway in cancer and is essential for tumor metabolism. Endometrial cancer has the highest frequency of PI3K pathway mutations of any solid tumor, yet there are no approved therapies addressing this need. FTH-001, a PI3Kα inhibitor, and FTH-003, an mTORC 1/2 inhibitor, have both demonstrated potential in multiple previous cancer clinical trials and their combination represents a unique “multi-node” approach to targeting this pathway.

[Click here](#) to view the press release.

NRG-GY018 Publication

naturemedicine

PUBLICATION

NRG GY018

PHASE 3 RANDOMIZED TRIAL


Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial

“

This paper highlights the clinical benefit of pembrolizumab in combination with chemotherapy and further reinforces the primary efficacy endpoints.

The findings support the use of pembrolizumab in combination with chemotherapy in patients with advanced stage or recurrent disease, irrespective of mismatch repair (MMR) status.

”



RAMEZ ESKANDER, MD
UNIVERSITY OF CALIFORNIA SAN DIEGO
CLINICAL TRIAL ADVISOR, GOG PARTNERS

GOG FOUNDATION®
Transforming the standard of care™

GOG PARTNERS

GOG FOUNDATION®
Transforming the standard of care™

GOG PARTNERS

[Click here](#) to read the full publication.

ENGOT-ov50 | GOG-3029 | INNOVATE-3 Publication



ScienceDirect®

PUBLICATION

ENGOT-ov50/

GOG-3029/ INNOVATE-3

Pivotal, Randomized, Open-label Study
of Tumor Treating Fields (TTFields,
200kHz) Concomitant With Weekly
Paclitaxel for the Treatment of
Recurrent Ovarian Cancer



“Platinum-resistant ovarian cancer presents a significant treatment challenge with limited effective options. While TTFields therapy did not show a significant survival benefit in the overall population, the exploratory post-hoc findings in PLD-naïve patients offer a promising direction for future research. We remain committed to investigating innovative therapies that address this critical unmet need, and we deeply appreciate the contributions of the patients and investigators involved in this study.”



DAVID O'MALLEY, MD
THE OHIO STATE UNIVERSITY,
JAMES CANCER CENTER
OVARIAN PORTFOLIO LEAD, GOG PARTNERS

[Click here](#) to read the full publication.

ON DEMAND EDUCATION

Accrual Culture: An Education Series on How to Build a Successful Clinical Trial Network

The purpose of this GOG Partners on-demand education series is to share key components for developing successful clinical trials. Our expert leaders will share their knowledge, experience, and best practices to integrate into your clinical trial process.

[Click here](#) to view this on-demand education today!

DID YOU KNOW

Shredding New Paths: Integrating Targeted Therapies in Ovarian and Endometrial Cancer – Clinical Runs and Future Slopes

The Shredding New Paths: Integrating Targeted Therapies in Ovarian and Endometrial Cancer – Clinical Runs and Future Slopes Industry Supported Symposium was presented at the 2025 SGO Winter Meeting on Thursday, January 30, 2025.

This course offers an in-depth exploration of the latest advancements in targeted therapies for endometrial and ovarian cancers, with a particular focus on antibody-drug conjugates (ADCs) and personalized treatment strategies. Participants will learn about the evolving landscape of cancer therapies, including the pivotal role of PARP inhibitor (PARPi) monotherapy in first-line maintenance treatment, examining its long-term efficacy and implications for patient outcomes in ovarian cancer.

[Click here](#) to view the recording and presentation slides.



GOG FOUNDATION®
Transforming the standard of care™

**Shredding New Paths:
Integrating Targeted
Therapies in Ovarian and
Endometrial Cancer – Clinical
Runs and Future Slopes**

An Industry Supported Symposium at the 2025 SGO Winter Meeting

THURSDAY
January 30, 2025

SESSION TIME
8:15 pm - 9:30 pm PT

GOG PARTNERS

The GOG Highlight Reel - January 2025

The GOG Highlight Reel is an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. A twice-yearly event, our most recent program took place Saturday, January 18, 2025, in Phoenix, Arizona alongside the 2025 NRG Oncology Winter Meeting.

The GOG Highlight reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.

[Click here](#) to view the recording and presentation slides.



Emerging Global Therapies in Clinical Trials in Progress for Endometrial and Ovarian Cancers, Understanding the Landscape and Optimizing Strategies

The Emerging Global Therapies in Clinical Trials in Progress for Endometrial and Ovarian Cancers, Understanding the Landscape and Optimizing Strategies Industry Supported Symposium was presented at the IGCS 2024 Annual Global Meeting in Dublin, Ireland.

This comprehensive course provides an in-depth exploration of clinical trials in progress for ovarian and endometrial cancers, offering valuable insights into ongoing research opportunities and competitive dynamics shaping the field. Participants will delve into key components of clinical trials, including study design, sequencing of trials, and learning about new opportunities for patients, gaining a solid understanding of the fundamentals essential for navigating research endeavors in these malignancies. Through dynamic discussions, participants will explore the ever-evolving competitive landscape of clinical trials in ovarian and endometrial cancers. Analyzing emerging therapies, novel treatment modalities, and investigational agents, attendees will gain insights into current trends and advancements influencing research directions and treatment paradigms. Join us for an enlightening journey through the intricacies of clinical trials in ovarian and endometrial cancers and equip yourself with the knowledge and skills to navigate the ever-evolving landscape of oncology research with confidence and expertise.

The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education associated with this Symposium: Gilead, Karyopharm Therapeutics, Genmab, ImmunoGen (now part of AbbVie), Corcept Therapeutics, and Sutro Biopharma.

[Click here](#) to view the recording and presentation slides.



Truth or Perception: Demystifying Emergent Data in the Competitive Endometrial Cancer Landscape

The Truth or Perception: Demystifying Emergent Data in the Competitive Endometrial Cancer Landscape Industry Supported Symposium at the IGCS 2024 Annual Global Meeting in Dublin, Ireland.

This educational program is aimed at providing clarity in the treatment landscape of endometrial cancers. With a focus on synthesizing emerging data and debunking misconceptions, this course aims to unravel the complexities surrounding the design of clinical trials and the significance of emerging biomarkers in the field. Throughout the session, participants will delve into key studies such as RUBY Parts I & II, GY018, ATTEND, DUO-E, B21 and other relevant endometrial trial data, exploring intriguing hypothesis-generating subgroup analyses, secondary endpoints, and trial eligibility nuances. Biomarkers, both prognostic and predictive, will be a pivotal topic of discussion, particularly exploring when and how clinicians obtain this information, how it is used to inform clinical trial results, and how it impacts clinical treatment decision-making. To foster interactive engagement, attendees will have the opportunity to ask questions about the studies to promote a dynamic and participatory learning experience. Through shorter talks and ample discussion time, participants will gain valuable insights and clarity on the ever-evolving landscape of endometrial cancer treatment.

The GOG Foundation, Inc. is grateful for our commercial supporter for this symposium: GSK

[Click here](#) to view the recording and presentation slides.



Expanding the Treatment Landscape for Recurrent Low-Grade Serous Ovarian Cancer

The Expanding the Treatment Landscape for Recurrent Low-Grade Serous Ovarian Cancer Industry Supported Symposium at the IGCS 2024 Annual Global Meeting in Dublin, Ireland.

Expert opinion leaders will engage with important educational updates and discussions on the evolving clinical landscape of low-grade serous ovarian cancer (LGSOC). LGSOC continues to have a high mortality rate, and better treatment options remain an unmet need. Recent studies indicate that therapies in the recurrent space support combination therapy treatment options. Expanding and improving the treatment landscape for recurrent LGSOC with practice changing medicines is a long-term goal to continue to enhance efficacy as well as quality of life for patients.

This non-promotional symposium is organized and funded by Verastem in collaboration with The GOG Foundation, Inc.

[Click here](#) to view the recording and presentation slides.



Personalized Management of Advanced or Recurrent

Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications

IGCS and Eisai welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the first presentation from the **Personalized Management of Advanced or Recurrent Endometrial Cancers: Navigating pMMR, dMMR Subtypes, or Molecular Classifications** Industry Supported Symposium presented at the IGCS 2024 Annual Global Meeting in Seoul, South Korea.

First Presentation:

pMMR vs dMMR Disease, Molecular Considerations in the Recurrent and First Line Setting

Presented By:

John Chan, MD, PhD

California Pacific Medical Center, Sutter Health, San Francisco, California, USA

Eisai has sponsored this initiative with IGCS and had no input into or influence over the content.

How To Access the Recording

You may access the recording on [IGCS Education360 Learning Portal](#) by logging into your IGCS account. If you do not have an IGCS account, you may create an account to view.

[Click here](#) to view recording.

If you are unsure of your IGCS account login information, please contact igcs@igcs.org.



UPCOMING INDUSTRY MEETINGS

2025 ASCO Annual Meeting

2025 ASCO
ANNUAL MEETING

The 2025 ASCO Annual Meeting will take place at McCormick Place in Chicago, Illinois on **May 30, 2025 - June 3, 2025**.

This meeting is a global gathering where oncology professionals connect, collaborate, and inspire. Known for advancing the field, this must-attend event offers an experience unlike any other, bringing together the best minds to shape the future of cancer care.

Deadline for early registration is Wednesday, April 23, 2025

[Click here](#) for more information on the 2025 ASCO Annual Meeting.

GCIG Meetings



GCIG Spring 2025 Meeting

- May 28 - 29, 2025
- Chicago, Illinois | Double Tree by Hilton Chicago

[Click here](#) for more information on the GCIG Spring 2025.

Pragmatic Trials Brainstorming Workshop

- May 28 - 29, 2025
- Chicago, Illinois

[Click here](#) for more information on the Pragmatic Trials Brainstorming Workshop.

GCIG Autumn 2025 Meeting

- Berlin, Germany

[Click here](#) for more information on the GCIG Fall Meeting.

2025 WAGO Annual Meeting

The 2025 WAGO Annual Meeting will be held at the Cheyenne Mountain Resort in Colorado Springs, Colorado on **June 18 - 21, 2025**.

The 2025 WAGO Annual Meeting will offer three days of science, education, and networking.

[Click here](#) for more information on the meeting.



ESMO Gynaecological Cancers Congress 2025

ESMO GYNAECOLOGICAL CANCERS
Annual Congress

VIENNA AUSTRIA
19-21 JUNE 2025



The 2025 ESMO Gynaecologic Cancers Congress will be held at the Austria Center in Vienna, Austria on **June 19 - 21, 2025**.

Once again, this edition will feature the innovative LIVE Plus format, which will provide a wealth of opportunities for exchange of ideas among delegates.

This conference is dedicated to advancing our understanding of gynecological cancers, including ovarian, cervical, uterine, vaginal, and vulvar cancers. Through a series of keynote lectures, panel discussions, and interactive sessions, we aim to foster collaboration, share cutting-edge research, and discuss innovative treatment modalities that are transforming patient care.

[Click here](#) for more information on the 2025 ESMO Gynaecological Cancers Congress!

NRG Oncology 2025 Summer Semiannual Meeting



The NRG Summer 2025 Semiannual Meeting will be held in person at the Marriott Marquis Hotel in Washington, D.C., from **July 24, 2025 – July 26, 2025**.

NRG Oncology will offer a full program that includes scientific sessions, engaged educational session for early-career investigators, and opportunities for networking events. We are excited to offer an expanded Summer Symposium. Learn more about the full program on the Agenda & Session Information page (coming soon!). Select sessions will be held virtually on July 14, 2025 – July 22, 2025, ahead of the in-person meeting.

Registration is anticipated to open mid-April.

The GOG Highlight Reel - July 2025



The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, medical oncologists,

advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to attend The GOG Highlight Reel - July 2025 education program presented in person at the **Marriott Marquis Hotel in Washington, D.C. on Saturday, July 26, 2025 from 9:30 am – 11:30 am ET.**

The July 2025 Highlight Reel will be offered in person only.

Registration is anticipated to open mid-April.

IGCS 2025 Annual Global Meeting

You are invited to the 2025 Annual Global Meeting of the International Gynecologic Cancer Society, which will be held at Century City Conference Centre in Cape Town, South Africa from **November 5-7, 2025.**



The IGCS Meeting is a platform for exchanging insights, sharing research findings, and discussing best practices. It's an opportunity to build professional networks, foster collaborations, and learn from some of the brightest minds in the field. Don't miss the chance to be part of this global community striving to make a difference in the lives of women affected by gynecologic cancers!

[Click here](#) for more information on the IGCS 2025 Annual Global Meeting!



GOG Foundation Inc. | Four Penn Center 1600 JFK Blvd. Suite 1020 | Philadelphia, PA 19103 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!